Recent research, such as the prospective study by Jin et al., has suggested that DLBCL exhibits moderate to strong fibroblast activation protein (FAP) expression, with all 34 patients in their cohort demonstrating positive lesions on FAPI PET. The gene discussed is FAP; the disease is diffuse large B-cell lymphoma.